Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- Efavirenz vs Boosted PIs in Treatment-Naive Patients
- Large-scale clinical trials have compared efavirenz to lopinavir/ritonavir[Riddler 2008] and to atazanavir + ritonavir[Sax 2009; Daar 2011]
- In ACTG 5142, efavirenz plus 2 NRTIs was found to be superior to lopinavir/ritonavir plus 2 NRTIs at Week 96 by the coprimary endpoint of time to virologic failure (P = .006).[Riddler 2008]
- In ACTG 5202, there was a similar time to virologic failure at the Week 96 primary endpoint analysis with atazanavir + ritonavir vs efavirenz when combined with either abacavir/lamivudine or emtricitabine/tenofovir DF[Daar 2011]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content